Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent

• US 7,192,736 B2
• Filed: 02/22/2001
• Issued: 03/20/2007
• Est. Priority Date: 07/22/1998
• Status: Expired due to Fees

• Current Assignee: Osprey Pharmaceuticals USA, Inc. (Osprey Pharmaceuticals Limited), Samsung Engineering Company Limited (Samsung Group)
• Original Assignee: Osprey Pharmaceuticals Limited
• Inventors: Coggins, Philip J., McDonald, John R.
• Primary Examiner(s): Landsman; Robert S.
• Application Number:
  US09/792,793
• Publication Number:
  US 20020168370A1
• Time in Patent Office: 2,217 Days
• Field of Search: 536/23.5, 424/85.1, 424/85.2
• US Class Current: 435/69.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/642 the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
• CPC Class Codes: A61K 47/6425 the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
• CPC Class Codes: A61K 47/6811 the drug being a protein or peptide, e.g. transferrin or bleomycin
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/415 from plants
• CPC Class Codes: C07K 14/521 Chemokines
• CPC Class Codes: C07K 2318/20 Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/01 containing a localisation/targetting motif
• CPC Class Codes: C07K 2319/55 containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Nucleic acid moleucles that encode conjugates containing as a ligand a chemokine receptor targeting agent, such as a chemokine, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophils, macrophages, and eosinophils.

Claims

1. A nucleic acid molecule, comprising a sequence of nucleotides encoding a conjugate that comprises a toxin and a chemokine receptor targeting agent, or a portion thereof sufficient for binding to a chemokine receptor and internalization of the chemokine receptor targeting agent, wherein:

the conjugate binds to a chemokine receptor resulting in internalization of the toxin in cells bearing the receptor; and

the receptor occurs on activated immune cells.

2. A nucleic acid molecule of claim 1, wherein the encoded conjugate comprises the following components:

(chemokine receptor targeting agent)_n, (L)_q and (toxin)_m, wherein;

L is a linker for linicing the chemokine receptor targeting agent to a toxin;

chemokine receptor targeting agent is any moiety that selectively binds to a chemokine receptor;

m and n, which are selected independently, are at least 1; and

q is 0 or more as long as the resulting conjugate binds to the targeted receptor, is internalized and delivers the toxin;

the resulting conjugate binds to a receptor that interacts with and internalizes a chemokine, whereby the toxin(s) is internalized in a cell bearing the receptor, and

when the conjugate contains a plurality of toxins the toxins are the same or different, and when the conjugate contains a plurality of chemokine receptor targeting agents the targeting agents are the same or different.

3. The nucleic acid molecule of claim 2, wherein m and n, which are selected independently, are 1–

6.

4. The nucleic acid molecule of claim 2, wherein q is 1, n is 2 and m is 1.

5. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the fragment binds to the receptor and internalizes the toxin.

6. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on activated leukocytes.

7. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on cells selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.

8. The nucleic acid molecule of claim 6, wherein the leukocytes are selected from basophils, neutrophils, eosinophils, and combinations of any two or more thereof.

9. The nucleic acid molecule of claim 1 that comprises DNA.

10. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent and targeting agent are joined via a linker.

11. The nucleic acid molecule of claim 10, wherein the linker is a peptide or an amino acid.

12. The nucleic acid molecule of claim 1, further comprising nucleic acid that encodes a non-chemokine cytokine or a receptor associated protein that binds to receptors on and/or activates one or more of the cells that promote secondary tissue damage, other than chemokine receptors.

13. The nucleic acid molecule of claim 12, wherein the cytokine binds to a cytokine-specific receptor expressed on cells that express chemokine receptors.

14. The nucleic acid molecule of claim 13, wherein the cytokine is selected from among interleukins, lymphokines, monokines, colony-stimulating factors and receptor associated proteins.

15. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent is a monoclonal antibody, or an antigen-specific fragment thereof.

16. The nucleic acid molecule of claim 1, further comprising nucleic acid that encodes an antibody that binds to a non-chemokine cytokine receptor and/or to a non-chemokine cytokine of claim 1.

17. A plasmid, comprising the nucleic acid molecule of claim 1.

18. A isolated host cell, comprising the plasmid of claim 17.

19. A method of producing a conjugate, comprising culturing the cell of claim 18 under conditions, whereby a fusion protein comprising the conjugate is expressed, and isolating the fusion protein.

20. A nucleic acid molecule of claim 1, wherein the chemokine is selected from the group consisting of eotaxin, stromal derived factor-1β

, SDF-1α

, monocyte chemotactic protein-1 (MCP-1), MCP-3, macrophage inhibitory protein-1α

(MIP-1α

), MIP-1β and

Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) protein.

21. A nucleic acid molecule of claim 1, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MIP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, Tim-1, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin, ALP, lungkine and fractalkine.

22. A nucleic acid molecule of claim 1 wherein the encoded conjugate is selected from among OPL98104, OPL98112, OPL98108, OPL98102, OPL98110, OPL98106, OPL98101, OPL98109, OPL98105, OPL98103, OPL98111 and OPL98107 ligand-toxin fusion gene constructs.

23. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting moiety effects binding to a receptor selected from the group consisting of CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, XCR1 and CX3CR-1, whereby the conjugate is internalized into a cell bearing the receptor.

24. The nucleic acid molecule of claim 1, wherein the toxin is a ribosome inactivating protein, a bacterial toxin or a fragment thereof that retains the ribosome inactivating or toxin activity.

25. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on immune effector cells.

26. The nucleic acid molecule of claim 1, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on cells selected from among monocytes, macrophages, leukocytes and microglia.